We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Eli Lilly wins Alzheimer's antibody patent dispute.
- Abstract
The article reports on the ruling of a Great Britain court which invalidates Janssen Pharmaceutica NV's patent for the flunked Alzheimer's disease therapy bapineuzumab. It says that Eli Lilly & Co. challenged to revoke the patent on the grounds including lack of description and detail for the invention. The court rules the overbroadness of the patent due to its lack of limit for antibodies targeting specific part of amyloid-β and the failure to make treatment as stated in the patent.
- Subjects
DRUG patents; LEGAL judgments; JANSSEN Pharmaceutica NV; ELI Lilly &; Co.; ALZHEIMER'S disease treatment
- Publication
Nature Reviews Drug Discovery, 2013, Vol 12, Issue 9, p656
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd4122